Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study.

Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P.

Lupus Sci Med. 2019 Nov 9;6(1):e000354. doi: 10.1136/lupus-2019-000354. eCollection 2019.

2.

MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis.

Bauer Y, White ES, de Bernard S, Cornelisse P, Leconte I, Morganti A, Roux S, Nayler O.

ERJ Open Res. 2017 Mar 22;3(1). pii: 00074-2016. doi: 10.1183/23120541.00074-2016. eCollection 2017 Jan.

3.

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.

Berger RMF, Gehin M, Beghetti M, Ivy D, Kusic-Pajic A, Cornelisse P, Grill S, Bonnet D; FUTURE-3 investigators.

Br J Clin Pharmacol. 2017 Aug;83(8):1734-1744. doi: 10.1111/bcp.13267. Epub 2017 Mar 23.

4.

Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial.

Steinhorn RH, Fineman J, Kusic-Pajic A, Cornelisse P, Gehin M, Nowbakht P, Pierce CM, Beghetti M; FUTURE-4 study investigators.

J Pediatr. 2016 Oct;177:90-96.e3. doi: 10.1016/j.jpeds.2016.06.078. Epub 2016 Aug 5.

PMID:
27502103
5.

Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort.

Allanore Y, Denton CP, Krieg T, Cornelisse P, Rosenberg D, Schwierin B, Matucci-Cerinic M; DUO Investigators.

Ann Rheum Dis. 2016 Sep;75(9):1736-40. doi: 10.1136/annrheumdis-2016-209481. Epub 2016 Jun 27. No abstract available.

6.

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.

Broijl A, Kersten MJ, Alemayehu WG, Levin MD, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GM, Wijermans PW, Lokhorst H, Sonneveld P.

Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11. No abstract available.

7.

Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry.

Matucci-Cerinic M, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Cornelisse P, Denton CP.

Ann Rheum Dis. 2016 Oct;75(10):1770-6. doi: 10.1136/annrheumdis-2015-208121. Epub 2015 Nov 26.

8.

Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.

Kappos L, Kuhle J, Multanen J, Kremenchutzky M, Verdun di Cantogno E, Cornelisse P, Lehr L, Casset-Semanaz F, Issard D, Uitdehaag BM.

J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1202-7. doi: 10.1136/jnnp-2014-310024. Epub 2015 Sep 15.

9.

Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study.

Patterson MC, Mengel E, Vanier MT, Schwierin B, Muller A, Cornelisse P, Pineda M; NPC Registry investigators.

Orphanet J Rare Dis. 2015 May 28;10:65. doi: 10.1186/s13023-015-0284-z.

10.

Scoring treatment response in patients with relapsing multiple sclerosis.

Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P, Stubinski B, Stromillo Ml, Montalban X, De Stefano N.

Mult Scler. 2013 Apr;19(5):605-12. doi: 10.1177/1352458512460605. Epub 2012 Sep 25.

PMID:
23012253
11.

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N.

Neurology. 2011 Nov 1;77(18):1684-90. doi: 10.1212/WNL.0b013e31823648b9. Epub 2011 Oct 5.

PMID:
21975200
12.

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Bruijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T, Minnema MC.

Blood. 2011 Sep 1;118(9):2413-9. doi: 10.1182/blood-2011-04-348292. Epub 2011 Jun 20.

PMID:
21690556
13.

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.

Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V.

Ther Adv Neurol Disord. 2011 Jan;4(1):3-14. doi: 10.1177/1756285610391693.

14.

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.

Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N.

Mult Scler. 2011 May;17(5):541-9. doi: 10.1177/1352458510391837. Epub 2010 Dec 9.

PMID:
21148262
15.

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.

Devonshire V, Arbizu T, Borre B, Lang M, Lugaresi A, Singer B, Verdun di Cantogno E, Cornelisse P.

BMC Neurol. 2010 Apr 30;10:28. doi: 10.1186/1471-2377-10-28.

16.

Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women.

van de Wijgert JH, Morrison CS, Cornelisse PG, Munjoma M, Moncada J, Awio P, Wang J, Van der Pol B, Chipato T, Salata RA, Padian NS.

J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):203-10. doi: 10.1097/QAI.0b013e3181743936.

PMID:
18520679
17.

Hormonal contraception and the risk of HIV acquisition.

Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, Mugerwa R, Padian N, Rugpao S, Brown JM, Cornelisse P, Salata RA; Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group.

AIDS. 2007 Jan 2;21(1):85-95.

PMID:
17148972
18.

Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion.

Colfax GN, Buchbinder SP, Cornelisse PG, Vittinghoff E, Mayer K, Celum C.

AIDS. 2002 Jul 26;16(11):1529-35.

PMID:
12131191
19.

Correlates of suicide attempts in an open cohort of young men who have sex with men.

Botnick MR, Heath KV, Cornelisse PG, Strathdee SA, Martindale SL, Hogg RS.

Can J Public Health. 2002 Jan-Feb;93(1):59-62.

20.

Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, Strathdee SA, Currie SL, Schechter MT, O'Shaughnessy MV.

CMAJ. 2001 Oct 2;165(7):889-95.

21.

HIV infection and risk behaviours among young gay and bisexual men in Vancouver.

Strathdee SA, Martindale SL, Cornelisse PG, Miller ML, Craib KJ, Schechter MT, O'Shaughnessy MV, Hogg RS.

CMAJ. 2000 Jan 11;162(1):21-5.

22.

Experience in treating persons with HIV/AIDS and the legalization of assisted suicide: the views of Canadian physicians.

Heath KV, Wood E, Bally G, Cornelisse PG, Hogg RS.

AIDS Care. 1999 Oct;11(5):501-10.

PMID:
10755026
23.

Comparison of sexual behaviors, unprotected sex, and substance use between two independent cohorts of gay and bisexual men.

Craib KJ, Weber AC, Cornelisse PG, Martindale SL, Miller ML, Schechter MT, Strathdee SA, Schilder A, Hogg RS.

AIDS. 2000 Feb 18;14(3):303-11.

PMID:
10716507
24.

The impact of zidovudine on dementia-free survival in a population of HIV-positive men and women on antiretroviral therapy.

Cornelisse PG, Montessori V, Yip B, Craib KJ, O'Shaughnessy MV, Montaner JS, Hogg RS.

Int J STD AIDS. 2000 Jan;11(1):52-6.

PMID:
10667902
25.

The social determinants of emergency department and hospital use by injection drug users in Canada.

Palepu A, Strathdee SA, Hogg RS, Anis AH, Rae S, Cornelisse PG, Patrick DM, O'Shaughnessy MV, Schechter MT.

J Urban Health. 1999 Dec;76(4):409-18.

26.

HIV-associated risk factors among young Canadian Aboriginal and non-Aboriginal men who have sex with men.

Heath KV, Cornelisse PG, Strathdee SA, Palepu A, Miller ML, Schechter MT, O'Shaughnessy MV, Hogg RS.

Int J STD AIDS. 1999 Sep;10(9):582-7.

PMID:
10492424
27.

Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak.

Schechter MT, Strathdee SA, Cornelisse PG, Currie S, Patrick DM, Rekart ML, O'Shaughnessy MV.

AIDS. 1999 Apr 16;13(6):F45-51.

PMID:
10397556
28.

Models of survival in HIV infection and their use in the quantification of treatment benefits.

Veugelers PJ, Cornelisse PG, Craib KJ, Marion SA, Hogg RS, Strathdee SA, Montaner JS, O'Shaughnessy MV, Schechter MT.

Am J Epidemiol. 1998 Sep 1;148(5):487-96.

PMID:
9737561
29.

Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.

Strathdee SA, Hogg RS, Martindale SL, Cornelisse PG, Craib KJ, Montaner JS, O'Shaughnessy MV, Schechter MT.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):61-6.

PMID:
9732071
30.

Barriers to use of free antiretroviral therapy in injection drug users.

Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, Schechter MT, Hogg RS.

JAMA. 1998 Aug 12;280(6):547-9.

PMID:
9707146
31.

Accuracy of oxygen delivery by liquid oxygen canisters.

Kampelmacher MJ, Cornelisse PB, Alsbach GP, van Kesteren RG, Melissant CF, Douze JM, Lammers JW.

Eur Respir J. 1998 Jul;12(1):204-7.

32.

Is AIDS a floating point between HIV seroconversion and death? Insights from the Tricontinental Seroconverter Study.

van Benthem BH, Veugelers PJ, Cornelisse PG, Strathdee SA, Kaldor JM, Shafer KA, Coutinho RA, van Griensven GJ.

AIDS. 1998 Jun 18;12(9):1039-45.

PMID:
9662201
33.

Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada.

Strathdee SA, Patrick DM, Archibald CP, Ofner M, Cornelisse PG, Rekart M, Schechter MT, O'Shaughnessy MV.

Addiction. 1997 Oct;92(10):1339-47.

PMID:
9489050
34.

Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver.

Patrick DM, Strathdee SA, Archibald CP, Ofner M, Craib KJ, Cornelisse PG, Schechter MT, Rekart ML, O'Shaughnessy MV.

Int J STD AIDS. 1997 Jul;8(7):437-45.

PMID:
9228591
35.

Needle exchange is not enough: lessons from the Vancouver injecting drug use study.

Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, Schechter MT, O'Shaughnessy MV.

AIDS. 1997 Jul;11(8):F59-65.

PMID:
9223727
36.

Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents.

Ostrow MJ, Cornelisse PG, Heath KV, Craib KJ, Schechter MT, O'Shaughnessy M, Montaner JS, Hogg RS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jun 1;15(2):115-20.

PMID:
9241109
37.

Determinants of HIV-related high risk behaviours among young offenders: a window of opportunity.

Rothon DA, Strathdee SA, Cook D, Cornelisse PG.

Can J Public Health. 1997 Jan-Feb;88(1):14-7.

38.

Bacterial and viral removal efficiency, heat and moisture exchange properties of four filtration devices.

Vanderbroucke-Grauls CM, Teeuw KB, Ballemans K, Lavooij C, Cornelisse PB, Verhoef J.

J Hosp Infect. 1995 Jan;29(1):45-56.

PMID:
7738339

Supplemental Content

Loading ...
Support Center